Document is current
Any future updates will be listed below
-
Authors
Nakanishi, Nobuhiro
Kaikita, Koichi
Ishii, Masanobu
Kuyama, Naoto
Tabata, Noriaki
Ito, Miwa
Yamanaga, Kenshi
Fujisue, Koichiro
Hoshiyama, Tadashi
Kanazawa, Hisanori
Hanatani, Shinsuke
Sueta, Daisuke
Takashio, Seiji
Arima, Yuichiro
Araki, Satoshi
Usuku, Hiroki
Nakamura, Taishi
Yamamoto, Eiichiro
Soejima, Hirofumi
Matsushita, Kenichi
Tsujita, Kenichi
-
Funding
Funding for this research was provided by:
Ministry of Education (#15K09089)
Ministry of Education (#18K08110)
- License Information
-
More Information
Article History
Received: 13 October 2022
Accepted: 13 February 2023
First Online: 6 March 2023
Declarations
:
: Dr. Koichi Kaikita has received remuneration for lecturing from Bayer Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd., Novartis Pharma AG., and Otsuka Pharmaceutical Co., Ltd.; trust research/joint research funds from SBI Pharmaceuticals Co., Ltd., Bayer Yakuhin, Ltd., and Daiichi-Sankyo Co., Ltd.; and scholarship funds from Abbott Medical Co., Ltd. Dr. Kenichi Tsujita has received remuneration for lecturing from Amgen Astellas BioPharma K.K., Bayer Yakuhin, Ltd., Bristol-Myers K.K., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co. Ltd., MSD K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., ITI Co., Ltd., trust research/joint research funds from Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., and scholarship funds from Abbott Medical Japan L.L.C, Abbott Vascular Japan Co., Ltd., Boston Scientific Japan K.K., Cardinal Health Japan, Chugai Pharmaceutical Co, Ltd., Fides-one, Inc., Fukuda Denshi Co., Ltd., Japan Lifeline Co., Ltd., Kaneka Medix Co., Ltd., Medtronic Japan Co., Ltd., Mitsubishi Tanabe Pharma, NIHON KOHDEN CORPORATION, NIPRO CORPORATION, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and TERUMO Co, Ltd.
